Thrombin

Related Products

Thrombin is a Na⁺-activated, serine protease which is activated by the enzymatic cleavage of two sites on prothrombin by activated Factor X. Thrombin exists in two allosteric forms, slow (S) and fast (F), target toward anticoagulant and procoagulant activities.

Thrombin is the main effector protease in primary hemostasis by activating platelets and plays a key role in secondary hemostasis. Besides its well-known functions in hemostasis, thrombin also plays a role in various non-hemostatic biological and pathophysiologic processes, predominantly mediated through activation of protease-activated receptors (PARs). PAR-1, PAR-3, and PAR-4 are cleaved by thrombin, whereas PAR-2 is cleaved by trypsin. Thrombin also plays a crucial role in the migration and metastasis of human cancer cells.

Thrombin Related Products (147)
Antibodies (9)

By Effects:	Substrates (2) Ligand (1) Inhibitors (107) Agonists (2) Antagonists (4) Activators (4)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-N8278

Dermatan sulphate sodium	Inhibitor
Dermatan sulphate sodium is an oral active glycosaminoglycan and thrombin inactivator with antithrombotic activity. It selectively catalyzes the heparin cofactor II-mediated inactivation of thrombin without interacting with antithrombin III. Dermatan sulphate sodium promotes stem cell differentiation, exhibits high bioavailability, and alleviates pulmonary fibrosis injury induced by Bleomycin (HY-108345). Dermatan sulphate sodium can be used in research related to cardiovascular diseases, inflammation, and stem cell differentiation.

HY-P2813

Hirudin	Inhibitor
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others.

HY-B0375A

Argatroban monohydrate	Inhibitor	99.98%
Argatroban (monohydrate) (MD-805 (monohydrate)) is a direct, selective thrombin inhibitor.

HY-P4349A

Pyr-Arg-Thr-Lys-Arg-AMC TFA	Substrate	99.53%
Pyr-Arg-Thr-Lys-Arg-AMC TFA is a AMC peptide. AMC is a decapeptide that is specifically hydrolyzed by proteases such as trypsin and thrombin. The AMC peptide can be used to determine the activity of protease and the potency of enzyme inhibitors.

HY-10264B

Edoxaban tosylate monohydrate	Inhibitor	99.97%
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research.

HY-17378

Dabigatran (ethyl ester)	Inhibitor	98.09%
Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.

HY-B0924

Anisindione	Inhibitor	98.07%
Anisindione is a synthetic anticoagulant. It inhibits the formation of active procoagulant factors II, VII, IX, and X.

HY-77521

Dabigatran ethyl ester hydrochloride	Inhibitor
Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) with an IC₅₀ value of 0.8 μM and a thrombin inhibitor.

HY-P99725

Marstacimab	Activator
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia.

HY-100897

Sulodexide	Inhibitor
Sulodexide is an orally active mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease.

HY-101054

NQ301		98.98%
NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC₅₀ of 10 mg/mL.

HY-P1000

TRAP-14	Agonist	98.00%
TRAP-14 (SFLLRNPNDKYEPF) is a synthetic thrombin receptor agonist peptide.

HY-129056

Melagatran	Inhibitor	99.31%
Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia. Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion.

HY-101918

DS-1040 Tosylate	Inhibitor	99.51%
DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC₅₀s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases.

HY-10163S1

Dabigatran-d₃	Inhibitor
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-P0316A

TP508 TFA	Antagonist	99.44%
TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues.

HY-163348

FXIIa-IN-4	Inhibitor	98.87%
FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC₅₀ of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant.

HY-P1741

Fibrinogen-Binding Peptide		99.83%
Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin.

HY-10264S

Edoxaban-d₆	Inhibitor	≥99.0%
Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment.

HY-107966A

Heparin calcium (MW 3600-5000)	Inhibitor
Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Thrombin

Thrombin

Thrombin Related Products (147)

Antibodies (9)

Thrombin Related Products (147):